ArtemiFlow names Adam Maust new CEO
Potsdam, Germany (January 14, 2019) — ArtemiFlow USA Inc. has named Adam J. Maust as CEO to lead their effort to become the world’s leading producer of artemisinin-derived medicines to cure malaria and cancer patients.
Researchers at the Max Planck Institute for Dynamics of Complex Technical Systems and the Max Planck Institute of Colloids and Interfaces in Potsdam, Germany have developed a new method, in which they use substances from plant waste to produce artemisinin. Artemisinin is an important component of the most effective anti-malaria drugs, and research is also being carried out on its potential use in the treatment of cancer. The new process, which can be industrialized on a massive scale, promises increased and low-cost production. For this reason, it is being industrialized by ArtemiFlow.
“Adam Maust has proven to have the experience, ingenuity, and the relationships needed to lead ArtemiFlow from the development stage into production at a massive scale,” said Dr. Peter Seeberger, the Founder of ArtemiFlow.
Drs. Seeberger and Gilmore developed proprietary technology for artemisinin production at the Max-Planck Institute for Colloids and Interfaces in Potsdam, Germany that has now been licensed exclusively to ArtemiFlow. The company has developed highly efficient processes to obtain and utilize components from the Sweet Wormwood plant, Artemisia annua. ArtemiFlow captures the entire value chain; plant production, extraction, chemical derivatization, and formulation of high quality drug products produced for the global market.
ArtemiFlow plans to build an extraction facility in Eastern/Central United States and utilize experienced farmers to plant thousands of acres of Artemisia annua.
Malaria is a disease that affects up to 200 million people a year. Artemisinin-based therapies are the most effective malaria treatment used throughout the world; however, supplies of artemisinin have been unstable in recent decades.
It is an easily treated disease with the medicine made from the artemisia plant, but hundreds of thousands of children die every year because they don’t have access to the medication.
“There are only two ways to fix the problem. Inject more money into the system and buy more medicine that is out there, or we can produce these medications more cheaply and efficiently. That is what we are intending to do and with Adam Maust’s leadership we are closer to making this a reality,” Dr. Kerry Gilmore said.
ArtemiFlow is also working with the Markey Cancer Center in Lexington, Kentucky to begin stage one human trials in the coming monthsutilizing artemisinin-based drugs against a large range of cancers.
“We have an opportunity to save hundreds of thousands of children’s lives that are lost every year to Malaria in third world countries. There is also immense promise in these same pharmaceutical drugs being used to fight cancers. We have something amazing here and I look forward to helping build it,” said Adam Maust.
Adam Maust has over 13 years of experience successfully managing hundreds of political campaigns throughout the country. Maust grew up in Somerset, PA and graduated from Roger Williams University, RI. Maust served as Political Director in Pennsylvania House Campaign Committee and was Partner at Red Maverick Media over the last 7 years. Maust has experience successfully building, organizing, consulting, and managing campaigns in Pennsylvania, Kentucky, Ohio, Maryland, and West Virginia.
ArtemiFlow has successfully planted a research test crop in Kentucky in partnership with the University of Kentucky College of Agriculture in 2018. ArtemiFlow is in the process of determining the location of their facility and operation.
Contact Dr. Kerry Gilmore: Gilmore@Artemiflow.com